CytomX Therapeutics, Inc.
CTMX
$2.03
$0.031.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -63.36% | 33.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -63.36% | 33.66% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -63.36% | 33.66% | |||
| SG&A Expenses | -29.76% | 67.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -29.52% | 38.61% | |||
| Operating Income | -105.68% | 27.95% | |||
| Income Before Tax | -100.39% | 24.55% | |||
| Income Tax Expenses | 1.61% | 0.00% | |||
| Earnings from Continuing Operations | -100.65% | 24.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -100.65% | 24.63% | |||
| EBIT | -105.68% | 27.95% | |||
| EBITDA | -104.08% | 27.16% | |||
| EPS Basic | -100.44% | 22.67% | |||
| Normalized Basic EPS | -100.24% | 22.61% | |||
| EPS Diluted | -100.44% | 22.67% | |||
| Normalized Diluted EPS | -100.24% | 22.61% | |||
| Average Basic Shares Outstanding | 48.16% | 1.61% | |||
| Average Diluted Shares Outstanding | 48.11% | 1.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||